219 related articles for article (PubMed ID: 15150565)
1. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.
Zuetenhorst JM; Korse CM; Bonfrer JM; Bakker RH; Taal BG
Br J Cancer; 2004 Jun; 90(11):2073-9. PubMed ID: 15150565
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
3. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.
Zuetenhorst JM; Bonfrer JM; Korse CM; Bakker R; van Tinteren H; Taal BG
Cancer; 2003 Apr; 97(7):1609-15. PubMed ID: 12655516
[TBL] [Abstract][Full Text] [Related]
4. Four decades of experience with carcinoid heart disease: An analysis of 84 patients.
Levy S; Korse CE; de Groot ACA; Meijer RCA; Tesselaar MET; Valk GD
J Neuroendocrinol; 2022 Oct; 34(10):e13199. PubMed ID: 36256859
[TBL] [Abstract][Full Text] [Related]
5. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Dobson R; Cuthbertson DJ; Jones J; Valle JW; Keevil B; Chadwick C; Poston GP; Burgess MI
Neuroendocrinology; 2014; 99(2):85-93. PubMed ID: 24603343
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of NT-proBNP in assessment of right ventricular function in children after tetralogy of Fallot correction - a preliminary study.
Pietrzak R; Werner B
Kardiol Pol; 2009 Apr; 67(4):378-83. PubMed ID: 19492250
[TBL] [Abstract][Full Text] [Related]
7. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
8. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease.
Elstein D; Nir A; Klutstein M; Abrahamov A; Zimran A
Pulm Pharmacol Ther; 2004; 17(5):319-23. PubMed ID: 15477128
[TBL] [Abstract][Full Text] [Related]
9. Carcinoid heart disease: case and literature review.
Dumoulein M; Verslype C; van Cutsem E; Meuris B; Herijgers P; Flameng W; Herregods MC
Acta Cardiol; 2010 Apr; 65(2):261-4. PubMed ID: 20458839
[TBL] [Abstract][Full Text] [Related]
10. Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease.
Lundin L; Landelius J; Andrén B; Oberg K
Br Heart J; 1990 Sep; 64(3):190-4. PubMed ID: 2206710
[TBL] [Abstract][Full Text] [Related]
11. Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance.
Moerman VM; Dewilde D; Hermans K
Acta Cardiol; 2012 Apr; 67(2):245-8. PubMed ID: 22641985
[TBL] [Abstract][Full Text] [Related]
12. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
Dong H; Chen DQ; Wang Y; Li M
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
[TBL] [Abstract][Full Text] [Related]
13. [Personal experience with determination of NT-proBNP in clinical practice].
Stejskal D; Oral I; Lacnák B; Juráková R; Horalík D; Adamovská S; Prosková J; Hrabovská I; Ozanová G
Vnitr Lek; 2003 Feb; 49(2):121-6. PubMed ID: 12728579
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century.
Bhattacharyya S; Toumpanakis C; Caplin ME; Davar J
Am J Cardiol; 2008 Feb; 101(3):378-81. PubMed ID: 18237604
[TBL] [Abstract][Full Text] [Related]
16. Two-dimensional echocardiography in the diagnosis of carcinoid heart disease.
Forman MB; Byrd BF; Oates JA; Robertson RM
Am Heart J; 1984 Mar; 107(3):492-6. PubMed ID: 6695693
[TBL] [Abstract][Full Text] [Related]
17. [Comparison study on diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
Li YJ; Wang L; Chen KY; Chen YL; Cai JR; Zhou LJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Sep; 17(9):544-7. PubMed ID: 16146600
[TBL] [Abstract][Full Text] [Related]
18. The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.
Johnson KKN; Stemann Lau T; Mark Dahl Baunwall S; Elisabeth Villadsen G; Guldbrand Rasmussen V; Grønbaek H; Oksjoki RK; Dam G
J Neuroendocrinol; 2023 Oct; 35(10):e13327. PubMed ID: 37574797
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Adults With Congenital Heart Disease.
Popelová JR; Kotaška K; Tomková M; Tomek J
Am J Cardiol; 2015 Nov; 116(9):1425-30. PubMed ID: 26404943
[TBL] [Abstract][Full Text] [Related]
20. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years.
Simula DV; Edwards WD; Tazelaar HD; Connolly HM; Schaff HV
Mayo Clin Proc; 2002 Feb; 77(2):139-47. PubMed ID: 11838647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
